Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients – A propensity scoring approach

Objective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared. Methods: Fifty-two patients with pathologically con...

Full description

Bibliographic Details
Main Authors: Kazuhiro Nagao, Hideyasu Matsuyama, Masahiro Nozawa, Isao Hara, Tsukasa Nishioka, Takahiro Komura, Atsunobu Esa, Shigeya Uejima, Masaaki Imanishi, Yasunari Uekado, Takatoshi Ogawa, Hiroshi Kajikawa, Hirotsugu Uemura
Format: Article
Language:English
Published: Elsevier 2016-01-01
Series:Asian Journal of Urology
Subjects:
Zoledronic acid
Hormone-naïve prostate cancer
Biochemical recurrence
Propensity score-match analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388215001149

Internet

http://www.sciencedirect.com/science/article/pii/S2214388215001149

Similar Items